cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.31143549
title: Additional file 39 of The "double-edged sword" effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of endometriosis (EMS)

description: Supplementary Material 39.
DOI: 10.6084/m9.figshare.31143549.v1
title: Additional file 39 of The "double-edged sword" effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of endometriosis (EMS)

description: Supplementary Material 39.
DOI: 10.6084/m9.figshare.31143552
title: Additional file 40 of The "double-edged sword" effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of endometriosis (EMS)

description: Supplementary Material 40.
DOI: 10.6084/m9.figshare.31143552.v1
title: Additional file 40 of The "double-edged sword" effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of endometriosis (EMS)

description: Supplementary Material 40.
DOI: 10.6084/m9.figshare.31143555
title: Additional file 41 of The "double-edged sword" effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of endometriosis (EMS)

description: Supplementary Material 41.
DOI: 10.6084/m9.figshare.31143555.v1
title: Additional file 41 of The "double-edged sword" effect of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of endometriosis (EMS)

description: Supplementary Material 41.
DOI: 10.6084/m9.figshare.31143570
title: Additional file 1 of Eco-friendly alternatives to seed chemical coating: agro-industrial byproducts as seed treatments with long-term effects on growth and reproduction

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.31143570.v1
title: Additional file 1 of Eco-friendly alternatives to seed chemical coating: agro-industrial byproducts as seed treatments with long-term effects on growth and reproduction

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.31143569
title: Additional file 1 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 1: Table S1. Summary of Gene Omission Errors.
DOI: 10.6084/m9.figshare.31143569.v1
title: Additional file 1 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 1: Table S1. Summary of Gene Omission Errors.
DOI: 10.6084/m9.figshare.31143572
title: Additional file 2 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 2: Table S2. Analysis of Proteins of Extreme Size.
DOI: 10.6084/m9.figshare.31143572.v1
title: Additional file 2 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 2: Table S2. Analysis of Proteins of Extreme Size.
DOI: 10.6084/m9.figshare.31143575
title: Additional file 3 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 3: Table S3. Status of KRTAP and LCE Genes in the 3 Pig Genomes.
DOI: 10.6084/m9.figshare.31143575.v1
title: Additional file 3 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 3: Table S3. Status of KRTAP and LCE Genes in the 3 Pig Genomes.
DOI: 10.6084/m9.figshare.31143578
title: Additional file 4 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 4: Table S4. Status of Retrotransposons and Retroviruses in the 3 Pig Genomes.
DOI: 10.6084/m9.figshare.31143578.v1
title: Additional file 4 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 4: Table S4. Status of Retrotransposons and Retroviruses in the 3 Pig Genomes.
DOI: 10.6084/m9.figshare.31143581
title: Additional file 5 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 5: Table S5. Summary of Build Errors in Selenoprotein Genes.
DOI: 10.6084/m9.figshare.31143581.v1
title: Additional file 5 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 5: Table S5. Summary of Build Errors in Selenoprotein Genes.
DOI: 10.6084/m9.figshare.31143584
title: Additional file 6 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 6: Table S6. Status of Mucin Genes in the 3 Pig Genomes .
DOI: 10.6084/m9.figshare.31143584.v1
title: Additional file 6 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 6: Table S6. Status of Mucin Genes in the 3 Pig Genomes .
DOI: 10.6084/m9.figshare.31143587
title: Additional file 7 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 7: Table S7. Status of Protocadherin Genes in the 3 Pig Genomes.
DOI: 10.6084/m9.figshare.31143587.v1
title: Additional file 7 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 7: Table S7. Status of Protocadherin Genes in the 3 Pig Genomes.
DOI: 10.6084/m9.figshare.31143590
title: Additional file 8 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 8: Table S8. Status of Readthrough Genes in the 3 Pig Genomes.
DOI: 10.6084/m9.figshare.31143590.v1
title: Additional file 8 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 8: Table S8. Status of Readthrough Genes in the 3 Pig Genomes.
DOI: 10.6084/m9.figshare.31143593
title: Additional file 9 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 9: Table S9. Microproteins.
DOI: 10.6084/m9.figshare.31143593.v1
title: Additional file 9 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 9: Table S9. Microproteins.
DOI: 10.6084/m9.figshare.31143596
title: Additional file 10 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 10: Table S10. Pig, Mouse and Human Gene and Total Protein Comparisons.
DOI: 10.6084/m9.figshare.31143596.v1
title: Additional file 10 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 10: Table S10. Pig, Mouse and Human Gene and Total Protein Comparisons.
DOI: 10.6084/m9.figshare.31143599
title: Additional file 11 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 11: Table S11. Analyses of Structural Domain Comparisons.
DOI: 10.6084/m9.figshare.31143599.v1
title: Additional file 11 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 11: Table S11. Analyses of Structural Domain Comparisons.
DOI: 10.6084/m9.figshare.31143602
title: Additional file 12 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 12: Table S12. Comparison of Genes with Low 5' and or 3 Conservation Between Humans and Pigs.
DOI: 10.6084/m9.figshare.31143602.v1
title: Additional file 12 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 12: Table S12. Comparison of Genes with Low 5' and or 3 Conservation Between Humans and Pigs.
DOI: 10.6084/m9.figshare.31143605
title: Additional file 13 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 13: Table S13. Summary of Conserved Swine/Human Splice Variants.
DOI: 10.6084/m9.figshare.31143605.v1
title: Additional file 13 of Verification and comparison of pig, mouse, and human genome similarities: use of manual assembly and analyses

description: Supplementary Material 13: Table S13. Summary of Conserved Swine/Human Splice Variants.
DOI: 10.6084/m9.figshare.31143626
title: Additional file 1 of TP53 mutations as drivers of chordoma progression and hallmarks of aggressive chordoma

description: Supplementary material 1.
DOI: 10.6084/m9.figshare.31143626.v1
title: Additional file 1 of TP53 mutations as drivers of chordoma progression and hallmarks of aggressive chordoma

description: Supplementary material 1.
DOI: 10.6084/m9.figshare.31143629
title: Additional file 2 of TP53 mutations as drivers of chordoma progression and hallmarks of aggressive chordoma

description: Supplementary material 2.
DOI: 10.6084/m9.figshare.31143629.v1
title: Additional file 2 of TP53 mutations as drivers of chordoma progression and hallmarks of aggressive chordoma

description: Supplementary material 2.
DOI: 10.6084/m9.figshare.31143632
title: Additional file 3 of TP53 mutations as drivers of chordoma progression and hallmarks of aggressive chordoma

description: Supplementary material 3.
DOI: 10.6084/m9.figshare.31143632.v1
title: Additional file 3 of TP53 mutations as drivers of chordoma progression and hallmarks of aggressive chordoma

description: Supplementary material 3.
DOI: 10.6084/m9.figshare.31143644
title: Additional file 3 of From cigarettes to symptoms: the association between smoking and depression in the German National Cohort (NAKO)

description: Supplementary Material 3.
DOI: 10.6084/m9.figshare.31143644.v1
title: Additional file 3 of From cigarettes to symptoms: the association between smoking and depression in the German National Cohort (NAKO)

description: Supplementary Material 3.
DOI: 10.15468/dl.s87q26
title: Occurrence Download

description: A dataset containing 260 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Anemocarpa saxatilis",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 260 records from 14 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008854-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ty36wc
title: Occurrence Download

description: A dataset containing 29706 records in GBIF matching the query:
SELECT
 '250' AS fish_cell,
 GBIF_MGRSCode(1000, decimalLatitude, decimalLongitude, 0) AS cell, -- NO randomization
 COUNT(DISTINCT speciesKey) AS species_richness
 FROM occurrence
 WHERE hasCoordinate = TRUE
 AND speciesKey IS NOT NULL
 AND NOT ARRAY_CONTAINS(issue, 'ZERO_COORDINATE')
 AND NOT ARRAY_CONTAINS(issue, 'COORDINATE_OUT_OF_RANGE')
 AND NOT ARRAY_CONTAINS(issue, 'COORDINATE_INVALID')
 AND NOT ARRAY_CONTAINS(issue, 'COUNTRY_COORDINATE_MISMATCH')
 AND decimalLatitude &gt;= 16.25916876999866
 AND decimalLatitude &lt;= 20.3845909579754
 AND decimalLongitude &gt;= -98.6537462863998
 AND decimalLongitude &lt;= -92.09228368724241
 AND "year" &gt;= 2015
 AND "year" &lt;= 2026
 AND (coordinateUncertaintyInMeters &lt;= 100 OR coordinateUncertaintyInMeters IS NULL)
 GROUP BY fish_cell, cell

 The dataset's 29706 records were derived from 295 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008850-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.34740/kaggle/dsv/14599271
title: Peer-to-Peer Boliviano (BOB) Exchange Data
DOI: 10.15468/dl.g5gg8x
title: Occurrence Download

description: A dataset containing 90 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is one of (Human Observation, Specimen)",
 "OccurrenceStatus is Present",
 "TaxonKey is Curculio caryatrypes"
 ]
}

 The dataset includes 90 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008855-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.pupe6d
title: Occurrence Download

description: A dataset containing 44 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Anisopappus anemonifolius",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 44 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0008856-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31143673
title: Supplementary Material for: MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy

description: Purpose: Describe the design and rationale of the MAGIC (ClinicalTrials.gov identifier, NCT05681884) trial assessing change in retinal non-perfusion (RNP) among eyes with non-proliferative diabetic retinopathy (NPDR) in sham and treated patients.
Design: Phase 2 prospective, randomized, multicenter, open-label, clinical trial.
Participants: Adults with NPDR and substantial RNP (&gt; 5 disc areas) on ultra-widefield fluorescein angiography (UWFA) images. 
Methods: Patients will be randomized (1:1) into 1 of 2 arms: Group 1 receiving intravitreal faricimab 6 mg every 4 weeks (Q4W) and Group 2 being observed Q16W. At 48 weeks, Group 1 will receive faricimab Q16W and Group 2 will initiate faricimab Q4W through the final trial endpoint at year 2. The primary endpoint is change in RNP area through week 48. Secondary endpoints include change in RNP area through week 96; percentage of neovascularization, vitreous hemorrhage, DME, and/or PDR development; change in best-corrected visual acuity (BCVA); change in central subfield thickness (CST); contrast sensitivity (CS) measured using the quantitative Contrast Sensitivity Function (qCSF); detection of apoptosing retinal cells (DARC) analysis; and proportion of subjects with ≥ 2-step improvement in Diabetic Retinopathy Severity Score (DRSS). Safety outcomes include incidence and severity of adverse events. 
Main Outcome Measures: Study design rationale.
Results: Recruitment commenced in May 2023 and was completed in May 2024. Group 1 will be dosed Q4W to maximize detection of an impact on RNP progression compared to the untreated Group 2. During year 2, Group 1 will be dosed Q16W to assess for maintenance of any changes in RNP trajectory achieved during year 1. Group 2 will assess the natural history of RNP progression through year 1, then transition to maximal dosing to evaluate for a potential change in trajectory of RNP progression. Additional assessments, including CS and DARC, will address the unmet need for a better understanding of visual dysfunction among patients with NPDR and investigate the potential role of apoptosis in RNP, respectively. 
Conclusions: MAGIC is a randomized clinical trial that assesses RNP progression among eyes with NPDR, including its natural history and the impact of faricimab. Its innovative study design also explores the utility of novel assessments of retinal physiology and function.
DOI: 10.6084/m9.figshare.31143673.v1
title: Supplementary Material for: MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy

description: Purpose: Describe the design and rationale of the MAGIC (ClinicalTrials.gov identifier, NCT05681884) trial assessing change in retinal non-perfusion (RNP) among eyes with non-proliferative diabetic retinopathy (NPDR) in sham and treated patients.
Design: Phase 2 prospective, randomized, multicenter, open-label, clinical trial.
Participants: Adults with NPDR and substantial RNP (&gt; 5 disc areas) on ultra-widefield fluorescein angiography (UWFA) images. 
Methods: Patients will be randomized (1:1) into 1 of 2 arms: Group 1 receiving intravitreal faricimab 6 mg every 4 weeks (Q4W) and Group 2 being observed Q16W. At 48 weeks, Group 1 will receive faricimab Q16W and Group 2 will initiate faricimab Q4W through the final trial endpoint at year 2. The primary endpoint is change in RNP area through week 48. Secondary endpoints include change in RNP area through week 96; percentage of neovascularization, vitreous hemorrhage, DME, and/or PDR development; change in best-corrected visual acuity (BCVA); change in central subfield thickness (CST); contrast sensitivity (CS) measured using the quantitative Contrast Sensitivity Function (qCSF); detection of apoptosing retinal cells (DARC) analysis; and proportion of subjects with ≥ 2-step improvement in Diabetic Retinopathy Severity Score (DRSS). Safety outcomes include incidence and severity of adverse events. 
Main Outcome Measures: Study design rationale.
Results: Recruitment commenced in May 2023 and was completed in May 2024. Group 1 will be dosed Q4W to maximize detection of an impact on RNP progression compared to the untreated Group 2. During year 2, Group 1 will be dosed Q16W to assess for maintenance of any changes in RNP trajectory achieved during year 1. Group 2 will assess the natural history of RNP progression through year 1, then transition to maximal dosing to evaluate for a potential change in trajectory of RNP progression. Additional assessments, including CS and DARC, will address the unmet need for a better understanding of visual dysfunction among patients with NPDR and investigate the potential role of apoptosis in RNP, respectively. 
Conclusions: MAGIC is a randomized clinical trial that assesses RNP progression among eyes with NPDR, including its natural history and the impact of faricimab. Its innovative study design also explores the utility of novel assessments of retinal physiology and function.
DOI: 10.6084/m9.figshare.31143676
title: Supplementary Material for: Lexical Processing of Children with Hearing Loss Using Bilateral Devices –Associations with Music Perception Skills

description: Introduction: Hearing loss (HL) poses a risk for challenges in lexical processing. While music perception skills are linked to improved lexical processing in normal hearing (NH) children, these connections are rarely evaluated in children with bilateral HL who use bilateral hearing devices. This study aimed to investigate lexical processing skills and their associations with music perception skills in children with bilateral HL to improve their assessment and rehabilitation. 

Methods: The study included 20 children aged 2 to 6 years with HL using bilateral cochlear implants, hearing aids, or bimodal devices from an early age and 26 age-matched peers with NH. Lexical processing was assessed through nonword repetition and semantic verbal fluency tasks. Music perception skills and background factors were evaluated using parent-reported questionnaires. 

Results: Children with HL were significantly outperformed by their NH peers in repeating segmental and prosodic aspects of nonwords. Linear regression analysis revealed that better music perception skills were linked to improved performance in nonword repetition and semantic verbal fluency tasks in both children with HL and NH. 

Conclusion: Children using bilateral hearing devices extensively from an early age had difficulties in early stages of lexical processing, measured with segmental and prosodic nonword repetition. It is essential to consider these skills when assessing lexical development and planning rehabilitation for young children with HL. The role of music perception in improving lexical processing in this population warrants investigation.
DOI: 10.6084/m9.figshare.31143676.v1
title: Supplementary Material for: Lexical Processing of Children with Hearing Loss Using Bilateral Devices –Associations with Music Perception Skills

description: Introduction: Hearing loss (HL) poses a risk for challenges in lexical processing. While music perception skills are linked to improved lexical processing in normal hearing (NH) children, these connections are rarely evaluated in children with bilateral HL who use bilateral hearing devices. This study aimed to investigate lexical processing skills and their associations with music perception skills in children with bilateral HL to improve their assessment and rehabilitation. 

Methods: The study included 20 children aged 2 to 6 years with HL using bilateral cochlear implants, hearing aids, or bimodal devices from an early age and 26 age-matched peers with NH. Lexical processing was assessed through nonword repetition and semantic verbal fluency tasks. Music perception skills and background factors were evaluated using parent-reported questionnaires. 

Results: Children with HL were significantly outperformed by their NH peers in repeating segmental and prosodic aspects of nonwords. Linear regression analysis revealed that better music perception skills were linked to improved performance in nonword repetition and semantic verbal fluency tasks in both children with HL and NH. 

Conclusion: Children using bilateral hearing devices extensively from an early age had difficulties in early stages of lexical processing, measured with segmental and prosodic nonword repetition. It is essential to consider these skills when assessing lexical development and planning rehabilitation for young children with HL. The role of music perception in improving lexical processing in this population warrants investigation.